Biotechnology stocks were falling on Wednesday after Food and Drug Administration Commissioner Scott Gottlieb said he is resigning from his post at the agency.
Salim Syed, senior biotech analyst at Mizuho Securities, told CNBC that Gottlieb represented a more"friendly FDA," adding he was"generally really liked by the biopharma investment community."Gottlieb is resigning to spend more time with his family, he said in a letter to FDA staff. The physician has been commuting from his home in Westport, Connecticut, where he has a wife and three young daughters.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:
because the new person isn't going to look past the negative health impacts